Summer Promo: $39/mo $85 with code SUMMER26 · See pricing →Limited Time Only
Comparison
Evaluate (EvaluatePharma) is the industry standard for consensus forecasts and valuation — built for strategy and finance teams. Salesmotion for Life Sciences is built for the people selling into sponsors, with contacts, signals, and outreach. They serve different jobs; here's an honest, sourced comparison.
By Semir JahicCEO & Co-Founder, SalesmotionLast reviewed | Feature | Evaluate | Salesmotion for Life Sciences |
|---|---|---|
| Primary Job | Consensus forecasting, valuation & market analysis | Commercial sponsor discovery, signals & outreach |
| Core Audience | Strategy, corporate development & finance teams | BD, sales, and commercial teams (CROs/CDMOs/labs) |
| Contact Data | None — not a prospecting/contact database | Verified decision-maker contacts (email + phone) |
| Outreach | None — not a sales-engagement or genAI tool | AI-drafted outreach anchored to the trigger |
| CRM / Salesforce | No documented CRM integration | Native Salesforce & HubSpot sync |
| Data Timing | Consensus forecasts can lag real-time events | Real-time ingestion from 40+ live sources |
| Pricing | Custom, enterprise-only, no public price | $85/mo for individuals. Custom pricing for teams & enterprise. |
| Rating (G2) | — | 4.8/5 |
Evaluate (founded 1996, London) is a commercial-intelligence and forecasting business for life sciences, now part of Norstella, the ~$5B life-sciences intelligence group. Its flagship, EvaluatePharma, is widely described as the industry standard for consensus drug-sales forecasts — 1.5M+ consensus forecasts of 10,000 products dating back to 2003, indication-level drug sales, pipeline intelligence, and deal and patent tracking. Evaluate Omnium adds ML-driven risk/return analysis for drug assets.
Evaluate is built for strategy, corporate development, and finance teams — forecasting, valuation, market sizing, and portfolio analysis. It is trusted across pharma, biotech, investment banks, and consultancies.
It is not a go-to-market tool. Evaluate provides no decision-maker contact data, no sales-engagement or AI outreach features (it is explicitly not a generative-AI platform), and no documented Salesforce/CRM integration. Its data is product- and company-level rather than patient-level, and because consensus forecasts depend on analyst coverage, they can lag real-time events. Pricing is custom and enterprise-only, with no public price.
Best for: Strategy, corporate development, and finance teams that need consensus forecasts, valuation, and portfolio/market analysis
Pricing: Custom, enterprise-only pricing — no public price, quote-based annual subscription. Evaluate is a Norstella company.
Salesmotion for Life Sciences is an AI-native sponsor-intelligence platform for the commercial side of life sciences — CROs, CDMOs, bioanalytical labs, and tools/equipment vendors selling into biotech and pharma. Where a forecasting platform answers "what is this market or asset worth?", Salesmotion answers the seller's question: "which sponsors should I pursue, why now, who do I contact, and what do I say?"
It continuously discovers and classifies sponsors from clinical trials (live from ClinicalTrials.gov and 40+ sources), regulatory filings, funding events, investor decks, and the open web, ranks 38,400+ drug developers and 410,000+ trials by fit to what you sell, and surfaces buying-window signals — first-in-human, phase transitions, readouts, funding — in real time rather than on an analyst-coverage cycle.
It carries the commercial execution layer a forecasting tool doesn't: verified decision-maker contacts with email and phone, one-click AI outreach anchored to the real trigger, and native Salesforce and HubSpot sync. Cytel, a 2,000+ person clinical-research organization, consolidated 5 tools into Salesmotion and cut research time by 50%.
Best for: Life-science BD and sales teams that need real-time sponsor discovery, buying signals, verified contacts, and outreach in one CRM-connected platform
G2 rating: 4.8/5
Pricing: $85/mo for individuals — flexible monthly billing. Custom pricing for teams and enterprise on request.
How Evaluate and Salesmotion for Life Sciences stack up across key capabilities.
| Feature | Evaluate | Salesmotion for Life Sciences |
|---|---|---|
| Consensus Forecasts | Core strength — industry-standard sales forecasts | Not a forecasting tool |
| Valuation & Market Sizing | Deep — indication-level sales, portfolio analysis | Not a valuation/market-sizing tool |
| Sponsor Discovery for Selling | Asset/market-oriented; not a prospecting workflow | Continuous discovery ranked by fit to what you sell |
| Buying Signals | Forecast and deal data; consensus can lag events | Real-time intent-tagged signals as buying windows open |
| Decision-Maker Contacts | Not included | Verified contacts with email and phone, per sponsor |
| AI Outreach | Not included (not a genAI platform) | AI drafts anchored to the trigger, push to CRM/Outlook |
| CRM Integration | None documented (Bloomberg data feed only) | Native Salesforce & HubSpot |
| Predictive Analytics | Evaluate Omnium — ML risk/return on assets | AI fit-scoring of sponsors for commercial fit |
| Setup & Time-to-Value | Enterprise onboarding | Live in days; no implementation project |
Evaluate is sold as a custom, enterprise-only subscription with no public price — quote-based and typically annual, which is standard for industry-benchmark forecasting data. Access is scoped by product (EvaluatePharma, Omnium, Epi) and seats.
Salesmotion for Life Sciences uses flexible, monthly pricing — individuals from $85/month, with custom team and enterprise pricing (unlimited users) and no annual lock-in. For a tailored quote based on your therapeutic areas, service lines, and integrations, book a demo.
The honest trade-off: these tools barely overlap. Evaluate is the gold standard for consensus forecasts, valuation, and market analysis — if that's your job, Salesmotion does not replace it. But Evaluate answers "what is this market or asset worth?", not "which sponsors do I sell to, who do I call, and what do I send?" It has no contact data, no outreach, and no CRM integration. For the commercial selling motion, Salesmotion is purpose-built. See how Cytel consolidated 5 tools into Salesmotion and cut research time by 50%.
We'd rather you pick the right tool than the wrong one. Salesmotion isn't for everyone — here's when another option on this page is the smarter call.
“All of the vendors that I've worked with, all of the onboarding that I have had to deal with, I will say, hands down, Salesmotion was the easiest that I have had.”
Lyndsay Thomson
Head of Sales Operations, Cytel
Salesmotion gives your reps the account intelligence they need to book more meetings and close bigger deals.
No. Evaluate (EvaluatePharma) is a forecasting and commercial-intelligence platform for strategy, corporate-development, and finance teams — consensus drug-sales forecasts, valuation, market sizing, and portfolio analysis. It provides no decision-maker contact data, no sales-engagement or AI outreach features, and no documented CRM integration. Salesmotion for Life Sciences is the commercial-execution tool: discovering sponsors to sell to, spotting buying windows, reaching decision-makers, and drafting outreach.
No. Evaluate is a market/forecast/financial intelligence platform — it does not provide names, emails, or phone numbers for prospecting, and it is explicitly not a generative-AI or sales-engagement tool. Salesmotion provides verified decision-maker contacts with email and phone on every sponsor profile, plus one-click AI outreach anchored to the real trigger and native Salesforce/HubSpot sync.
Only if you weren't using Evaluate for forecasting. Evaluate is the industry standard for consensus forecasts and valuation, and Salesmotion does not replicate that analytical depth. The two tools serve different jobs — Evaluate informs strategy and finance decisions, while Salesmotion drives the commercial selling motion. Teams that use Evaluate for forecasting and Salesmotion for BD and sales are using each for what it does best.
Consensus forecasts aggregate analyst coverage, so they update as analysts revise their models — which means they can lag real-time events like a fresh trial readout or a new raise. That's fine for valuation and strategy, the job Evaluate is built for. But for selling, timing is everything: Salesmotion surfaces buying-window signals in real time from 40+ live sources, so reps reach a sponsor when the window opens rather than after the forecast catches up.
Evaluate is part of Norstella, the roughly $5 billion life-sciences intelligence group formed through the 2021–2022 mergers that also brought together Citeline, MMIT, Panalgo, and The Dedham Group. So Evaluate (forecasting) and Citeline (pipeline and trials) are sister brands under the same parent. Neither is built for the commercial prospecting-to-outreach workflow that Salesmotion focuses on.
A Signal Agent, Research Agent, and Outreach Agent — working 24/7 so your team spends less time researching and more time closing.
